CENTROX, RELIANT, ULTROX, AS-D+, AS-E, AS-G, AS-J, AS-K AND AS-L
Device Facts
| Record ID | K101154 |
|---|---|
| Device Name | CENTROX, RELIANT, ULTROX, AS-D+, AS-E, AS-G, AS-J, AS-K AND AS-L |
| Applicant | Airsep Corp. |
| Product Code | CAW · Anesthesiology |
| Decision Date | Mar 28, 2011 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 868.5440 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The intended use of the device is to generate and deliver USP 93% oxygen for supplemental oxygen use only or filling cylinders. The device must not be used for or with any lifesupporting applications. The device is intended to be used only by trained personnel in hospitals, health care facilities or remote locations where bottled oxygen is not readily available. The instruction manual of the device recommends an alternate source of supplemental oxygen in the event of a power outage, alarm condition, or mechanical failure,
Device Story
Centrox, Ultrox, and Reliant oxygen concentrators utilize Pressure Swing Adsorption (PSA) to generate USP 93% oxygen from ambient air. System components include an air compressor, particulate/foam filters, coalescing filters, and adsorber vessels containing inert ceramic molecular sieve. Operation involves compressing ambient air, filtering contaminants, and passing air through molecular sieve to adsorb nitrogen under pressure, allowing oxygen to exit as product gas. While one adsorber produces oxygen, the other depressurizes to exhaust waste gases. Integrated oxygen analyzers monitor purity and trigger alarms if levels fall outside safe ranges. Devices are operated by trained personnel in clinical or remote settings. Output is used for supplemental oxygen or cylinder filling. The system is not for life support; an alternate oxygen source is required for power outages or mechanical failures.
Clinical Evidence
Bench testing only. Verification and validation included internal and external testing. Performance testing confirmed oxygen flow rate and purity (USP 93%) at specified operating pressures. Testing evaluated the impact of overdrawing, component failure, and valve cycling on device parameters. Independent laboratory testing verified oxygen purity and confirmed total volatile organic compounds (VOCs) and particulates were below accepted standards. Electrical safety and EMC compliance were confirmed.
Technological Characteristics
Pressure Swing Adsorption (PSA) oxygen generator. Materials include inert ceramic molecular sieve. Features integrated oxygen analyzer with alarm. Flow rates: 17-32 scfh; delivery pressure: 20-50 psig. Powered by air compressor. Standalone operation. Validated for USP 93% purity. No software algorithm class specified.
Indications for Use
Indicated for supplemental oxygen therapy or cylinder filling in patients requiring oxygen. Intended for use by trained personnel in hospitals, healthcare facilities, or remote locations. Contraindicated for life-supporting applications.
Regulatory Classification
Identification
A portable oxygen generator is a device that is intended to release oxygen for respiratory therapy by means of either a chemical reaction or physical means (e.g., a molecular sieve).
Predicate Devices
Submission Summary (Full Text)
{0}------------------------------------------------
K101154
MAR 2 8 2011
## 510(k) Summary
#### Submitter
Airsep Corporation 401 Creekside Drive Buffalo, NY 14228 Phone: (716) 691-0202
(716) 691-4141 Fax:
Registration Number: 1319044
## Contact person
Peter Weisenborn
Email: pweisenborn@airsep.com
#### Preparation Date
March 25, 2011
#### Device
#### Trade Name:
Centrox, Ultrox and Reliant Oxygen Concentrators Classification Name: Generator, Oxygen. Regulation Number: 868.5440 Product Code: CAW Device Class: Class II Classification Panel: Anesthesiology and Respiratory Therapy Devices
#### Predicate Devices
NewLife Intensity from AirSep Corporation Product code: CA W 510(k) number: K960309
Portable Oxygen Generator with Medical Air (POGS 33C) from On Site Gas Systems, Inc. Product code: CAW 510(k) number: K063454
{1}------------------------------------------------
## Device Description
Air contains 21 % oxygen, 78% nitrogen, 0.9% argon, and 0.1% other gases. AirSep PSA Oxygen units separate this small percentage of oxygen from the compressed air through a unique Pressure Swing Adsorption (PSA) process. The compressed air flows through a filter assembly before the air enters the adsorber vessels. A particulate/foam filter removes condensed water, oil, dirt, scale, etc. from the feed air, and then, a separate coalescing filter (if present) removes additional oil and water vapor.
The oxygen generator uses in its adsorber vessels an inert ceramic material called molecular sieve to separate compressed air into oxygen and other gases. The unique properties of molecular sieve allow it to attract, or adsorb, nitrogen physically from air under pressure. This allows oxygen to exit the adsorbers as a product gas.
While one adsorber produces oxygen, the other depressurizes to exhaust the waste gases it adsorbed (collected) during the oxygen production cycle. The entire oxygen generating process is completely regenerative, which makes it both reliable and virtually maintenancefree. The molecular sieve does not normally require replacement.
The medical devices in this submission refer to the following oxygen concentrators manufactured by AirSep Corporation:
| Model | Flow (scfh) | Oxygen Delivery<br>Pressure (psig) |
|---------|-------------|------------------------------------|
| Centrox | 32 | 50 |
| Ultrox | 17 | 20 |
| Reliant | 17 | 50 |
All of these devices are designed to deliver the oxygen with USP 93 % purity. Centrox and Reliant units are also available for cylinder filling option. Ultrox is used only to fill cylinders.
Centrox, Ultrox and Reliant units are comprised of an air compressor that uses ambient air to produce higher pressure feed air.
These models have the same indications for use. Together these products are referred to as Device.
The device is intended to be USP 93% oxygen generator. As such, to assure the purity, an Oxygen Analyzer is integrated in each device and an alarm is activated if the purity is outside of the safe range.
{2}------------------------------------------------
#### Intended Use
The intended use of the device is to generate and deliver USP 93% oxygen for supplemental oxygen use only or filling cylinders. The device must not be used for or with any lifesupporting applications. The device is intended to be used only by trained personnel in hospitals, health care facilities or remote locations where bottled oxygen is not readily available. The instruction manual of the device recommends an alternate source of supplemental oxygen in the event of a power outage, alarm condition, or mechanical failure,
#### Technological Characteristics
The comparison table is provided as a summary of the technological characteristics relative to the predicate devices. Items like intended use, principle of operation, oxygen purity, inlet pressure and flow rates are compared. All major components used in the system are also compared. The primary difference between the device and the respective predicate devices is in the flow rates which is a result of the size of the units. The performance of the device to produce the desired flowrates at specified purity and delivery pressure has been validated. The summary of the comparison table demonstrates that the device has no significant differences from the predicate devices that would adversely affect product safety and effectiveness.
## Testing
The device has been tested and verified in various phases, internal testing, verification and validation as well as external testing and validation. The design was verified throughout the design process. Risk analysis was done, appropriate measures were implemented and their effectiveness verified. External test house was used to confirm compliance to EMC requirements and standards for electrical safety.
#### Performance Data
The oxygen flow rate and purity at the operating pressure as specified in the instruction manual was tested and verified. The variation of oxygen purity and output pressure with the amount of overdrawing, the variation in parameters due to failure of components, the effect of improper valve cycling on the device parameters were tested and the ability of every device to deliver USP 93% oxygen was verified.
Independent laboratory testing also verified that the oxygen purity was in accordance with USP 93% and that the total Volatile organic compounds (VOC's) and particulates were well below accepted standards.
The results of this testing prove the safety and effectiveness of the device.
{3}------------------------------------------------
## Conclusion
The device performance tests demonstrate substantial equivalence to the predicate devices. The performance tests results also confirm ability to provide USP 93% oxygen for supplemental oxygen use only and for filling cylinders safely and effectively.
.
.
{4}------------------------------------------------
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the bird symbol.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Mr. Peter Weisenborn Vice President-Resources and Regulatory Affairs Airsep Corporation 401 Creekside Drive Buffalo, New York 14228-2085
MAR 2 8 2011
Re: K101154
Trade/Device Name: Centrox, Ultrox and Reliant Oxygen Concentrators ("Device") Regulation Number: 21 CFR 868.5440 Regulation Name: Portable Oxygen Generator Regulatory Class: II Product Code: CAW Dated: March 21, 2011 Received: March 24, 2011
Dear Mr. Weisenborn:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{5}------------------------------------------------
Page 2- Mr. Weisenborn
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm 115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/ default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-firee number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Nh for
Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
Applicant: Airsep Corporation
## 510(k) Number (if known): K101154
Device Name: Centrox, Ultrox and Reliant Oxygen Concentrators ( "Device")
# Indications For Use:
The intended use of the Device is to generate and deliver USP 93% oxygen for supplemental oxygen use only or filling cylinders. The device must not be used for or with any life-supporting applications.
The Device is intended to be used only by trained personnel in hospitals, health care facilities or remote locations where bottled oxygen is not readily available.
The instruction manual of the device recommends an alternate source of supplemental oxygen in the event of a power outage, alarm condition, or mechanical failure.
Prescription Use X AND/OR 801 Subpart D) (21 CFR 801 Subpart C)
Over-The-Counter Use _ _ _ _ (Part 21 CFR
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
h
(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices
510(k) Number:
(Optional Format 3-10-98)
rev A
